1. Home
  2. GFUZ vs EOLS Comparison

GFUZ vs EOLS Comparison

Compare GFUZ & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GFUZ

General Fusion Group Ltd. Common Shares

N/A

Current Price

$7.71

Market Cap

687.0M

Sector

Utilities

ML Signal

N/A

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$9.06

Market Cap

550.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GFUZ
EOLS
Founded
N/A
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
687.0M
550.9M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
GFUZ
EOLS
Price
$7.71
$9.06
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$15.50
AVG Volume (30 Days)
180.8K
1.1M
Earning Date
N/A
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1.23
EPS
N/A
N/A
Revenue
N/A
$297,176,000.00
Revenue This Year
N/A
$13.27
Revenue Next Year
N/A
$17.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.61
52 Week Low
$6.08
$3.86
52 Week High
$11.00
$9.15

Technical Indicators

Market Signals
Indicator
GFUZ
EOLS
Relative Strength Index (RSI) 49.30 71.54
Support Level $6.08 $5.78
Resistance Level $10.03 N/A
Average True Range (ATR) 0.71 0.38
MACD 0.02 0.04
Stochastic Oscillator 43.31 96.50

Price Performance

Historical Comparison
GFUZ
EOLS

About GFUZ General Fusion Group Ltd. Common Shares

General Fusion Group Ltd is focused on developing fusion energy technology based on Magnetized Target Fusion (MTF), which combines magnetic confinement and mechanical compression to achieve fusion conditions. It operates a large-scale demonstration system, Lawson Machine 26 (LM26), intended to validate elements of its technology and support the development of commercial fusion power plants for electricity generation.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: